Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Gastroenterology. 2010 Mar 6;138(7):2321–2331.e2. doi: 10.1053/j.gastro.2010.02.058

Gastroesophageal varices in peginterferon treated and untreated patients. 3A). Amongst the 598 patients without baseline varices, 302 were randomized to receive peginterferon and 296 to receive no further treatment. By year 4, the proportion of patients with new varices in the treated and untreated groups was similar (27% vs 26%, p= 0.81). In addition, the distribution of the types of varices that were detected was similar (p=0.06) 3B). Amongst the 210 patients with baseline gastroesophageal varices, 99 received peginterferon and 111 received no further antiviral treatment. By year 4, the proportion of patients with worsening, stable, and improved varices was similar (p=0.35).

Gastroesophageal varices in peginterferon treated and untreated patients. 3A). Amongst the 598 patients without baseline varices, 302 were randomized to receive peginterferon and 296 to receive no further treatment. By year 4, the proportion of patients with new varices in the treated and untreated groups was similar (27% vs 26%, p= 0.81). In addition, the distribution of the types of varices that were detected was similar (p=0.06) 3B). Amongst the 210 patients with baseline gastroesophageal varices, 99 received peginterferon and 111 received no further antiviral treatment. By year 4, the proportion of patients with worsening, stable, and improved varices was similar (p=0.35).